Scientific Areas of Expertise: Biological Circuits; Computational Biology; Genomics
For expertly developing and applying sophisticated computational modeling techniques and algorithms to understand molecular circuits and predict cellular behavior in response to genetic and environmental changes, cellular differentiation, evolution, and disease, and for developing microfluidic and other technologies for high throughput, single-cell genetic screening technologies.
A computational systems biologist, Dr. Regev is globally esteemed for expertly crafting and applying sophisticated computational modeling techniques and algorithms to understand molecular circuits and predict cellular behavior in response to genetic and environmental changes, cellular differentiation, evolution, and disease. Dr. Regev has pioneered the use of single-cell genomics and other techniques to dissect the molecular networks that regulate genes, define cells and tissues, and influence health and disease. Her multidisciplinary research has provided novel insights into gene regulatory networks governing cellular function during disease states ranging from autoimmune disease to cancer. Importantly, her group has developed microfluidic approaches to support high throughput single-cell genetic screening technologies, which hold strong potential to inform future therapeutic advancements.
Notably, Dr. Regev is a pioneer in developing and applying single-cell and spatial genomics to construct tumor atlases, conducting the first single-cell genomics study of a solid tumor (glioblastoma) and the first single cell study of a full tumor ecosystem (in melanoma). Since then, she has honed this approach with a “toolbox” of multiple experimental methods and AI algorithms and applied them to a wide variety of tumors and their microenvironments, including melanoma, colorectal cancer, pancreatic cancer, breast cancer, head and neck cancer, leukemia, sarcoma, ovarian cancer, and many brain tumors. This approach has delivered key insights into the biology of tumors and their response to therapy, such as revealing tumor type heterogeneity within an individual tumor; identifying potential combination therapies to overcome resistance to immunotherapy; and dissecting antitumor immunity, including in response to new therapies such as CAR-T cells. Her work laid the groundwork for the Human Tumor Atlas Network project.
Selected Awards and Honors
2021 Vanderbilt Prize in Biomedical Science, Vanderbilt University Medical Center, Nashville, Tennessee
2021 AACR-Irving Weinstein Foundation Distinguished Lectureship, Association for American Cancer Research, Philadelphia, Pennsylvania
2021 Ernst Schering Prize, Ernst Schering Foundation, Berlin, Germany
2021 James Prize in Science and Technology Integration, National Academy of Sciences, Washington, DC
2020 Elected Member, National Academy of Medicine, Washington, DC
2020 Keio Medical Science Prize, Keio University, Tokyo, Japan
2020 Helmholtz International Fellow Award, German Federal Ministry of Education and Research, Berlin, Germany
2020 Lurie Prize in Biomedical Sciences, Foundation for the National Institutes of Health, Bethesda, Maryland
2020 Jonathan Kraft Prize for Excellence in Cancer Research, Massachusetts General Hospital Cancer Center, Boston, Massachusetts
2019 Elected Member, National Academy of Sciences, Washington, DC
2019 Excellence in Science Award, Federation of American Societies for Experimental Biology, Rockville, Maryland
2017 Paul Marks Prize for Cancer Research, Memorial Sloan Kettering Cancer Center, New York, New York
2017 Innovator Award, International Society for Computational Biology, Leesburg, Virginia
2016 Elected Fellow, International Society for Computational Biology, Leesburg, Virginia
2014 Earl and Thressa Stadtman Scholar Award, American Society for Biochemistry and Molecular Biology, Rockville, Maryland
2008 Overton Prize, International Society for Computational Biology, Leesburg, Virginia